One Man Let Snakes Bite Him 200 Times. His Blood May Rewrite Antivenom Science

Tim Friede didn't set out to become a medical anomaly. The 58-year-old from Wisconsin started keeping exotic snakes the way some people collect stamps, drawn to the danger and the biology. But over nearly two decades, his hobby transformed into something far stranger and arguably more consequential: a self-directed immunization program in which he allowed some of the world's deadliest snakes to bite him, repeatedly and deliberately, more than 200 times.

The result, researchers now believe, is a bloodstream carrying extraordinarily potent broadly neutralizing antibodies, the kind that don't just fight one snake's venom but potentially many. That's not a small distinction. It may be the difference between a medical system that requires dozens of different antivenoms, each painstakingly matched to a specific species, and one that could treat a far wider range of bites with a single therapy.

Snakebite envenomation kills somewhere between 81,000 and 138,000 people every year, according to the World Health Organization, and leaves roughly three times that number with permanent disabilities, amputations, or disfigurement. The WHO formally classified snakebite as a neglected tropical disease in 2017, a designation that reflects both the scale of the suffering and the degree to which it has been ignored by wealthy-country pharmaceutical markets. Most victims are subsistence farmers in sub-Saharan Africa, South Asia, and rural Southeast Asia, people with little purchasing power and therefore little pull on the incentives that drive drug development.

The antivenom that does exist is expensive to produce, requires refrigeration that rural clinics often can't guarantee, and is frequently species-specific, meaning a vial produced against an Indian cobra offers little protection against an African mamba. Misidentification of the biting snake, which happens constantly in low-resource settings, can make treatment worse than useless. The system, in short, is fragile, inequitable, and badly overdue for disruption.

Friede's antibodies, isolated by a research team including scientists from the Scripps Research Institute and the biotech company Centivax, appear to neutralize venom across a remarkable range of elapid snakes, the family that includes cobras, mambas, and taipans. In a study published in the journal Cell in 2025, the researchers described a three-antibody cocktail derived partly from Friede's blood that protected mice against lethal doses of venom from 13 of 19 elapid species tested, with partial protection on several others. That breadth is, by the standards of antivenom research, extraordinary.

The urgency behind this research is not static. As global temperatures rise, the geographic ranges of venomous snakes are shifting. Warmer winters allow species to survive at higher altitudes and latitudes. Habitat destruction pushes snakes into agricultural land and peri-urban areas where human contact becomes more likely. A 2022 analysis in the Lancet Planetary Health projected that climate change could significantly expand the range of several highly venomous species, increasing the population exposed to snakebite risk in regions that currently have little antivenom infrastructure or clinical experience treating envenomation.

This is the second-order consequence that rarely makes the headline: the communities least responsible for carbon emissions are disproportionately positioned in the tropical and subtropical zones where snakebite risk is already highest, and where climate-driven range expansion will hit hardest. A failure to develop affordable, broadly effective antivenom isn't just a pharmaceutical gap. It's a compounding climate justice problem.

Friede himself is disarmingly direct about what he did and why. He has said publicly that he wanted to "put his ass on the line" for something that mattered. He nearly died at least once during his self-experimentation, and he did it without institutional support, without a clinical protocol, and without any guarantee that his suffering would produce anything useful. That it apparently has is a testament to both his unusual physiology and the researchers who recognized what his blood might contain.

The path from a promising mouse study to a human antivenom is long, expensive, and uncertain. Regulatory approval, manufacturing scale-up, cold-chain logistics, and pricing structures will all determine whether this science reaches the farmers and children who need it most. But the underlying immunological discovery, that the human body can, under extreme conditions, generate antibodies capable of broadly neutralizing snake venom, opens a conceptual door that was previously closed.

If those antibodies can be synthesized reliably and cheaply, the entire architecture of antivenom production, built around hyperimmunized horses and species-specific serums since the 1890s, may finally be ready for replacement. The question is whether the pharmaceutical economics will allow it to happen fast enough for the people already in the path of a warming world's expanding serpent geography.